References
- Iglay K, Hannachi H, Engel SS, et al. Comorbidities in type 2 diabetes patients with and without atherosclerotic cardiovascular disease: a retrospective database analysis. Curr Med Res Opin. 2021. DOI:https://doi.org/10.1080/03007995.2021.1895736.
- Alonso-Morán E, Orueta JF, Fraile Esteban JI, et al. The prevalence of diabetes-related complications and multimorbidity in the population with type 2 diabetes mellitus in the Basque Country. BMC Public Health. 2014;14:1059.
- Fox CS, Sullivan L, D'Agostino RB, Sr, et al. Framingham heart study. The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study. Diabetes Care. 2004;27(3):704–708.
- Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17(1):83.
- Muzurović EM, Mikhailidis DP. Diabetes mellitus and noncardiac atherosclerotic vascular disease-pathogenesis and pharmacological treatment options. J Cardiovasc Pharmacol Ther. 2021;26(1):25–39.
- Katsiki N, Mikhailidis DP. Diabetes and carotid artery disease: a narrative review. Ann Transl Med. 2020;8(19):1280.
- Muzurović E, Vujošević S, Mikhailidis DP. Can we decrease epicardial and pericardial fat in patients with diabetes? J Cardiovasc Pharmacol Ther. 2021. DOI:https://doi.org/10.1177/10742484211006997.
- Muzurović E, Dragnić S, Medenica S, et al. Weight-centric pharmacological management of type 2 diabetes mellitus - An essential component of cardiovascular disease prevention. J Diabetes Complications. 2020;34(8):107619.
- Stols-Gonçalves D, Hovingh GK, Nieuwdorp M, et al. NAFLD and atherosclerosis: two sides of the same dysmetabolic coin? Trends Endocrinol Metab. 2019;30(12):891–902.